The KRAS protein stimulates multiple downstream effector pathways, which are activated in a growth factor-independent way in cancer cells expressing oncogenic KRAS.1–3 The high frequency of KRAS mutations in human cancers (~20%) makes these proteins a potential target for antitumour therapy. The gene discussed is KRAS; the disease is cancer.